The Role and Mechanism of the Histone Methyltransferase G9a in Tumors: Update

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Jun 4

PMID 38832355

Authors

Hangsheng Zhou

Jiandong Gui

Lijie Zhu

Yuanyuan Mi

Affiliations

Soon will be listed here.

Abstract

Methylation-mediated gene silencing is closely related to the occurrence and development of human tumors. The euchromatic histone lysine methyltransferase 2 (EHMT2, also known as G9a) is highly expressed in many tumors and is generally considered to be an oncogene, which is associated with the poor outcome of many tumors. Combined immunotherapy and immune checkpoint blockade therapy also have good efficacy and certain safety. However, there are still many difficulties in the drugs targeting G9a, and the combined effect and safety of G9a with many drugs is still under study. This article aims to summarize the role and mechanism of G9a and its inhibitors in tumors in the past two years, and to understand the application prospect of G9a from the perspective of diagnosis and treatment.

Citing Articles

Dual Roles of microRNA-122 in Hepatocellular Carcinoma and Breast Cancer Progression and Metastasis: A Comprehensive Review.

Al Ageeli E Curr Issues Mol Biol. 2024; 46(11):11975-11992.

PMID: 39590305 PMC: 11592835. DOI: 10.3390/cimb46110711.

References

Friedrich M . Epigenetic therapies offer new approach to fighting cancer at the genetic level. JAMA. 2010; 303(3):213-4. DOI: 10.1001/jama.2009.1914. View

Huang Z, Huang J, Huang C, Hou Y, Zhu B . Euchromatic histone lysine methyltransferase 2 facilitates radioresistance in prostate cancer by repressing endoplasmic reticulum protein 29 transcription. Kaohsiung J Med Sci. 2023; 39(6):576-586. DOI: 10.1002/kjm2.12661. View

Jin Y, Park S, Park S, Lee C, Eum D, Shim J . G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer. Int J Mol Sci. 2022; 23(2). PMC: 8776044. DOI: 10.3390/ijms23020589. View

Colyn L, Alvarez-Sola G, Latasa M, Uriarte I, Herranz J, Arechederra M . New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. J Exp Clin Cancer Res. 2022; 41(1):183. PMC: 9134609. DOI: 10.1186/s13046-022-02386-2. View

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

Mu Y, Zou S, Li M, Ding Y, Huang X, He Z . Role and mechanism of FOXG1-related epigenetic modifications in cisplatin-induced hair cell damage. Front Mol Neurosci. 2023; 16:1064579. PMC: 10169754. DOI: 10.3389/fnmol.2023.1064579. View

Pribluda A, Daemen A, Lima A, Wang X, Hafner M, Poon C . EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS tumor development and propagation. Elife. 2022; 11. PMC: 9439681. DOI: 10.7554/eLife.57648. View

De Beck L, Awad R, Basso V, Casares N, De Ridder K, De Vlaeminck Y . Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Front Immunol. 2022; 13:799636. PMC: 9134079. DOI: 10.3389/fimmu.2022.799636. View

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

10.

Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M . G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 2002; 16(14):1779-91. PMC: 186403. DOI: 10.1101/gad.989402. View

11.

Colyn L, Barcena-Varela M, Alvarez-Sola G, Latasa M, Uriarte I, Santamaria E . Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology. 2020; 73(6):2380-2396. DOI: 10.1002/hep.31642. View

12.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

13.

Wang W, Wang J, Liu S, Ren Y, Wang J, Liu S . An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. Mol Cancer. 2022; 21(1):106. PMC: 9044593. DOI: 10.1186/s12943-022-01579-9. View

14.

Lee S, Hyeon D, Yoon S, Jeong J, Han S, Jang J . RUNX3 methylation drives hypoxia-induced cell proliferation and antiapoptosis in early tumorigenesis. Cell Death Differ. 2020; 28(4):1251-1269. PMC: 8027031. DOI: 10.1038/s41418-020-00647-1. View

15.

Iglesias N, Currie M, Jih G, Paulo J, Siuti N, Kalocsay M . Automethylation-induced conformational switch in Clr4 (Suv39h) maintains epigenetic stability. Nature. 2018; 560(7719):504-508. PMC: 6287498. DOI: 10.1038/s41586-018-0398-2. View

16.

Claveria-Cabello A, Herranz J, Latasa M, Arechederra M, Uriarte I, Pineda-Lucena A . Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. J Hepatol. 2023; 79(4):989-1005. DOI: 10.1016/j.jhep.2023.05.031. View

17.

Jana A, Naga R, Saha S, Banerjee D . 3D QSAR pharmacophore based lead identification of G9a lysine methyltransferase towards epigenetic therapeutics. J Biomol Struct Dyn. 2022; 41(18):8635-8653. DOI: 10.1080/07391102.2022.2135600. View

18.

Hou Q, Xiao Q, Sun X, Ju X, Luo Z . TBC1D3 promotes neural progenitor proliferation by suppressing the histone methyltransferase G9a. Sci Adv. 2021; 7(3). PMC: 7810367. DOI: 10.1126/sciadv.aba8053. View

19.

De Smedt E, Devin J, Muylaert C, Robert N, Requirand G, Vlummens P . G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. Blood Adv. 2021; 5(9):2325-2338. PMC: 8114552. DOI: 10.1182/bloodadvances.2020003217. View

20.

Hansen A, Ge Y, Schuster M, Pundhir S, Jakobsen J, Kalvisa A . H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway. Sci Adv. 2022; 8(11):eabf8627. PMC: 8932663. DOI: 10.1126/sciadv.abf8627. View